Premium
P4‐209: Safety, tolerability, pharmacokinetics and pharmacodynamics of monthly and quarterly doses of Ponezumab (PF‐04360365) in subjects with mild‐to‐moderate Alzheimer's disease
Author(s) -
Landen Jaren,
Andreasen Niels,
Cronenberger Carol,
Schwartz Pam,
BörjessonHanson Anne,
Östlund Henrik,
Sattler Catherine,
Kupiec James,
Binneman Brendon,
Bednar Martin
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1914
Subject(s) - tolerability , medicine , cohort , pharmacodynamics , pharmacokinetics , placebo , adverse effect , cerebrospinal fluid , gastroenterology , pharmacology , pathology , alternative medicine